Physician profile
Stefanija P Galovska
NPI 1649603663
$960.42
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.13 · 2022: $176 · 2023: $435 · 2024: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648 · Education: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $647.99 |
| Education | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $229.23 | 2022-2024 | Prolia, Evenity |
| Radius Health, INC. | $217.55 | 2021-2024 | Tymlos |
| Medtronic, INC. | $143.49 | 2022-2024 | Stealthstation S8 Platform, Space-D System 5.5/6.0 Voyager Instrument Set |
| Alvogen INC | $107.57 | 2022-2024 | Teriparatide |
| Csl Behring | $63.19 | 2024 | Kcentra |
| Azurity Pharmaceuticals, INC. | $61.13 | 2023 | Gliadel |
| Abbott Laboratories | $44.52 | 2024 | Proclaim |
| Orthofix Medical, INC. | $22.13 | 2023 | Spinal-Stim, Spinal-Stim, Cervical-Stim |
| Alexion Pharmaceuticals, INC. | $21.69 | 2023 | Strensiq |
| Stryker Corporation | $18.40 | 2021 | |
| Spineology INC. | $18.19 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefanija Galovska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.